Macquarie Group LTD C4 Therapeutics, Inc. Transaction History
Macquarie Group LTD
- $86.4 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
126Shares Held
63MCall Options Held
651KPut Options Held
115K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$14.8 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$14.5 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$12.9 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$10.3 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$9.65 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $104M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...